Clinical trial
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large…
NCT00118209 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00118209 |
|---|---|
| Title | Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma |
| Official title | Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Large B Cell Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide, filgrastim, pegfilgrastim |
| Enrollment | 524 |
| Start date | May 1, 2005 |
| Primary completion | Oct 1, 2017 |
| Completion | Nov 15, 2021 |
| First posted | Jul 11, 2005 |
| Last update posted | Nov 17, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: